325 related articles for article (PubMed ID: 31704279)
41. Severe infusion reaction due to nivolumab: A case report.
Kumari S; Yun J; Soares JR; Ding PN
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1246. PubMed ID: 32671983
[TBL] [Abstract][Full Text] [Related]
42. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
43. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
44. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
45. Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
Khaddour K; Singh V; Shayuk M
BMC Cancer; 2019 May; 19(1):449. PubMed ID: 31088420
[TBL] [Abstract][Full Text] [Related]
46. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
47. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Goldstein DA; Ratain MJ; Saltz LB
JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
[No Abstract] [Full Text] [Related]
48. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
49. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Kano H; Ichihara E; Harada D; Inoue K; Kayatani H; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Ninomiya K; Hotta K; Maeda Y; Kiura K
Cancer Sci; 2020 Oct; 111(10):3739-3746. PubMed ID: 32726470
[TBL] [Abstract][Full Text] [Related]
50. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
51. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract][Full Text] [Related]
52. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
[TBL] [Abstract][Full Text] [Related]
53. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
54. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
55. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
[TBL] [Abstract][Full Text] [Related]
57. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Abdayem P; Planchard D
Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
[No Abstract] [Full Text] [Related]
58. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
Kim Y; Kim CH; Lee HY; Lee SH; Kim HS; Lee S; Cha H; Hong S; Kim K; Seo SW; Sun JM; Ahn MJ; Ahn JS; Park K
J Thorac Oncol; 2019 Sep; 14(9):1608-1618. PubMed ID: 31195179
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.
Kim J; Kim T; Jang TW; Kang H; Kim MH; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Han JY; Kang EJ
Thorac Cancer; 2022 Aug; 13(15):2170-2179. PubMed ID: 35785522
[TBL] [Abstract][Full Text] [Related]
60. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
